Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Fabhalta® (iptacopan) – New indication
March 21, 2025 - Novartis announced the FDA approval of a new indication for Fabhalta (iptacopan), for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
